Cargando…

The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life

BACKGROUND: Hunter syndrome (mucopolysaccharidosis type II (MPS II)) is a rare metabolic disease that can severely compromise health, well-being and life expectancy. Little evidence has been published on the impact of MPS II on health-related quality of life (HRQL). The objective of this study was t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raluy-Callado, Mireia, Chen, Wen-Hung, Whiteman, David A H, Fang, Juanzhi, Wiklund, Ingela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722040/ https://www.ncbi.nlm.nih.gov/pubmed/23837440 http://dx.doi.org/10.1186/1750-1172-8-101

Ejemplares similares

The Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS) Questionnaire: item reduction and further validation
por: Wiklund, Ingela, et al.
Publicado: (2014)

Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future
por: Whiteman, David AH, et al.
Publicado: (2017)

Clinical Presentation of Mucopolysaccharidosis Type II (Hunter's Syndrome)
por: Chinawa, JM, et al.
Publicado: (2012)

Validation of the shortened Hunter Syndrome-Functional Outcomes for Clinical Understanding Scale (HS-FOCUS)
por: Mattera, Maria, et al.
Publicado: (2018)

Diagnosis and Management of Mucopolysaccharidosis Type II (Hunter Syndrome) in Poland
por: Żuber, Zbigniew, et al.
Publicado: (2023)

Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
por: Link, Bianca, et al.
Publicado: (2010)

Carpal Tunnel Syndrome in the Setting of Mucopolysaccharidosis II (Hunter Syndrome)
por: Argenta, Anne E., et al.
Publicado: (2017)

Atypical clinical presentation of mucopolysaccharidosis type II (Hunter syndrome): a case report
por: Shah, Gauri Shankar, et al.
Publicado: (2010)

Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II - Hunter syndrome
por: Chiong, Mary Anne D., et al.
Publicado: (2017)

Cochlear Implantation via the Transmeatal Approach in an Adolescent with Hunter Syndrome—Type II Mucopolysaccharidosis
por: Kim, Hantai, et al.
Publicado: (2021)

A rare case of mucopolysaccharidosis: Hunter syndrome
por: Gajula, Prathima, et al.
Publicado: (2012)

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)
por: Pano, Arian, et al.
Publicado: (2015)

Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)
por: Cho, Sung Yoon, et al.
Publicado: (2014)

Perioperative airway management for aortic valve replacement in an adult with mucopolysaccharidosis type II (Hunter syndrome)
por: Suzuki, Kazuchika, et al.
Publicado: (2018)

Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl
por: Semyachkina, A. N., et al.
Publicado: (2019)

Identification and Functional Characterization of IDS Gene Mutations Underlying Taiwanese Hunter Syndrome (Mucopolysaccharidosis Type II)
por: Lin, Hsiang-Yu, et al.
Publicado: (2019)

Birth weight in patients with mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Bodamer, Olaf, et al.
Publicado: (2017)

Challenges in the Management of Mucopolysaccharidosis Type II (Hunter's Syndrome) in a Developing Country: a Case Report
por: Rasheeedah, Ibraheem, et al.
Publicado: (2015)

Identification of 17 novel mutations in 40 Argentinean unrelated families with mucopolysaccharidosis type II (Hunter syndrome)
por: Amartino, H., et al.
Publicado: (2014)

Recovery of Vision following Enzyme Replacement Therapy in a Patient with Mucopolysaccharidosis Type II, Hunter Syndrome
por: Yamanishi, Ryutaro, et al.
Publicado: (2019)

Analysis of long-term observations of the large group of Russian patients with Hunter syndrome (mucopolysaccharidosis type II)
por: Semyachkina, Alla Nikolaevna, et al.
Publicado: (2021)

Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
por: Wraith, J. Edmond, et al.
Publicado: (2007)

Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): Contribution of genotype to cognitive developmental course
por: Seo, Joo-Hyun, et al.
Publicado: (2020)

Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS)
por: Ficicioglu, Can, et al.
Publicado: (2017)

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)
por: Sohn, Young Bae, et al.
Publicado: (2013)

Measuring patient experiences in Fabry disease: validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)
por: Ramaswami, Uma, et al.
Publicado: (2012)

Clinical characteristics and surgical history of Taiwanese patients with mucopolysaccharidosis type II: data from the hunter outcome survey (HOS)
por: Lin, Hsiang-Yu, et al.
Publicado: (2018)

Clinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2017)

Osteoarthropathy in mucopolysaccharidosis type II
por: NASCU, IOANA, et al.
Publicado: (2013)

Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report
por: Tomita, Kazuyoshi, et al.
Publicado: (2021)

Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: An analysis from the Hunter Outcome Survey
por: Lau, Heather, et al.
Publicado: (2023)

Cervical spondylolisthesis in mucopolysaccharidosis type II
por: Rossi, Alessandro, et al.
Publicado: (2022)

Development of a mnemonic screening tool for identifying subjects with Hunter syndrome
por: Cohn, Gabriel M., et al.
Publicado: (2013)

Biomarkers in patients with mucopolysaccharidosis type II and IV
por: Fujitsuka, Honoka, et al.
Publicado: (2019)

Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013
por: Raluy-Callado, Mireia, et al.
Publicado: (2015)

A retrospective study to assess resource utilization in patients with cervical dystonia in the United Kingdom
por: Raluy-Callado, Mireia, et al.
Publicado: (2015)

Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update
por: Burton, Barbara K., et al.
Publicado: (2020)

Mucopolysaccharidosis Type II: A Kenyan Case Series
por: Mungai, L. N. Wainaina, et al.
Publicado: (2021)

Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)
por: Muenzer, Joseph, et al.
Publicado: (2021)

COPD exacerbations by disease severity in England
por: Merinopoulou, Evie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gq2dmlgfeokscfo9lqfrh6ire1